Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 10/05/2024 am IST			5-day change	1st Jan Change
2.14 ^USD	-24.11%		-32.70%	-58.45%

15/04	Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	CI
15/04	Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

April 15, 2024 at 05:52 pm IST

Reviva Pharmaceuticals Holdings, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 39.26 million compared to USD 28.26 million a year ago. Basic loss per share from continuing operations was USD 1.65 compared to USD 1.45 a year ago.

Latest news about Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	15/04	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04	CI
Reviva Pharmaceuticals Closes $30 Million Registered Direct Offering	21/11	MT
Reviva Pharmaceuticals Holdings, Inc. announced that it has received $2.999942 million in funding	20/11	CI
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	17/11	MT
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading	17/11	MT
Sector Update: Health Care	17/11	MT
Reviva Pharmaceuticals Launching $30 Million Registered Direct Offering; Shares Fall	16/11	MT
Reviva Pharmaceuticals to Seek Acquisitions	16/11	CI
Reviva Pharmaceuticals Holdings, Inc. announced that it expects to receive $2.999942 million in funding	15/11	CI
Reviva Pharmaceuticals Holdings Q3 Loss Widens	15/11	MT
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
HC Wainwright Raises Reviva Pharmaceuticals' Price Target to $20 From $10, Keeps Buy Rating	31/23/31	MT
Sector Update: Health Care Stocks Gain Late Afternoon	31/23/31	MT
Sector Update: Health Care	31/23/31	MT
Reviva Shares Surge After Late-Stage Schizophrenia Trial Meets Primary Endpoint	31/23/31	MT
Top Midday Gainers	31/23/31	MT
Reviva Pharmaceuticals Says Phase 3 RECOVER Trial of Brilaroxazine in Adults With Schizophrenia Meets Primary Endpoint	30/23/30	MT
Reviva Pharma's schizophrenia drug succeeds in late-stage study	30/23/30	RE
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia	30/23/30	CI
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Monday	25/23/25	MT
Reviva Pharmaceuticals Says Last Patient Evaluated in Phase 3 Trial of Brilaroxazine to Treat Schizophrenia	25/23/25	MT
Roth MKM Initiates Reviva Pharmaceuticals With Buy Rating, Price Target is $12	20/23/20	MT
Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Completion for Pivotal Phase 3 Recover Study for Brilaroxazine in Schizophrenia	17/23/17	CI
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI

Chart Reviva Pharmaceuticals Holdings, Inc.

Duration

Period

Chart Reviva Pharmaceuticals Holdings, Inc.

More charts

Company Profile

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Companyâs pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimerâs disease (BPSD), and Parkinsonâs disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

Sector

Biotechnology & Medical Research

Calendar

13/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.14 USD

Average target price

17.4 USD

Spread / Average Target

+713.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
REVIVA PHARMACEUTICALS HOLDINGS, INC.	-58.45%	59.75M
MODERNA, INC.	+23.37%	47.02B
LONZA GROUP AG	+49.84%	41.86B
IQVIA HOLDINGS INC.	-0.94%	41.76B
CELLTRION, INC.	-4.32%	28.8B
ICON PUBLIC LIMITED COMPANY	+11.29%	26.05B
ALNYLAM PHARMACEUTICALS, INC.	-20.92%	19.15B
BIO-TECHNE CORPORATION	+3.20%	12.55B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	11.82B
MEDPACE HOLDINGS, INC.	+30.23%	12.34B

Other Biotechnology & Medical Research